{"id":4271,"date":"2019-11-25T13:52:00","date_gmt":"2019-11-25T12:52:00","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4271"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"risdiplam-in-der-u-s-zulassungsprozedur-und-bekommt-hohe-prioritaet","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/risdiplam-in-der-u-s-zulassungsprozedur-und-bekommt-hohe-prioritaet\/","title":{"rendered":"Risdiplam in der U.S. Zulassungsprozedur und bekommt hohe Priorit\u00e4t"},"content":{"rendered":"\n<p class=\"tw-text-wide\">Die <strong><a rel=\"noreferrer noopener\" aria-label=\"U.S. Food &amp; Drug Administration (\u00f6ffnet in einem neuem Tab)\" href=\"https:\/\/www.fda.gov\/\" target=\"_blank\">U.S. Food &amp; Drug Administration<\/a><\/strong>, kurz FDA hat die Einreichung zur Zulassung von Roche&#8217;s Risdiplam akzeptiert und erteilt zus\u00e4tzlich den <a rel=\"noreferrer noopener\" aria-label=\"Priority Review (\u00f6ffnet in einem neuem Tab)\" href=\"https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/priority-review\" target=\"_blank\"><strong>Priority Review<\/strong><\/a> &#8220;Status&#8221; wodurch sich eine z\u00fcgigere Zulassungprozedur und damit schnellere Verf\u00fcgbarkeit ergeben sollte. <\/p>\n\n\n\n<p class=\"tw-text-wide\">Vorraussichtlich schon bis zum 24.Mai 2020 soll die Entscheidung zur Zulassung von Risdiplam im Wirkungsbereich der FDA gef\u00e4llt werden.<\/p>\n\n\n\n<p class=\"tw-text-wide\"><em>Quelle: <\/em><a rel=\"noreferrer noopener\" aria-label=\" Roche Media Release (\u00f6ffnet in einem neuem Tab)\" href=\"https:\/\/www.roche.com\/media\/releases\/med-cor-2019-11-25.htm\" target=\"_blank\"><strong>Roche Media Release<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die U.S. Food &amp; Drug Administration, kurz FDA hat die Einreichung zur Zulassung von Roche&#8217;s Risdiplam akzeptiert und erteilt zus\u00e4tzlich den Priority Review &#8220;Status&#8221; wodurch sich eine z\u00fcgigere Zulassungprozedur und damit schnellere Verf\u00fcgbarkeit ergeben sollte. Vorraussichtlich schon bis zum 24.Mai 2020 soll die Entscheidung zur Zulassung von Risdiplam im Wirkungsbereich der FDA gef\u00e4llt werden. Quelle: [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"local","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4271","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4271"}],"version-history":[{"count":2,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4271\/revisions"}],"predecessor-version":[{"id":39922,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4271\/revisions\/39922"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}